Skip to main content
Erschienen in:

27.02.2024 | IM-Point of view

Contrasting obesity: is something missing here?

verfasst von: Agostino Di Ciaula, Piero Portincasa

Erschienen in: Internal and Emergency Medicine | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

The fight against obesity is largely based on recommendations about lifestyle and therapies to initiate weight loss and, hopefully, to achieve and maintain an ideal weight. The failure of this approach is witnessed by the steady increasing rates of obesity worldwide. Lifestyle modifications yield mild weight loss with poor results in the long-term. The pharmaceutical industry is engaged to produce the best anti-obesity drugs, and this market is projected to grow massively. Guidelines on pharmacological and surgical approach to obesity are continuously developed, taking into account that benefits are counterbalanced by high costs, are limited to the period of drug intake, and potential adverse effects are possible, such as pancreatitis, gastroparesis, and bowel obstruction. Meantime, people living with obesity might simply think that taking the “magic pill” or undergoing bariatric surgery can change their life. In the long term, this tendency might lead to scarce cost-effectiveness, increasing adverse effects and inequities in the most vulnerable age classes. Furthermore, the main actors responsible for generating an obesogenic world will continue undisturbed to produce negative effects. Obesity is not only generated from voluntary individual behaviors, and no guideline can truly counteract the detrimental effects of environmental factors driving the progressive rise of obesity globally. Unsustainable food production, packaging and marketing, environmental pollution, widely diffused endocrine disrupting chemicals, and climate change are largely neglected by health professionals and generate food insecurity and malnutrition. The complexity of obesity cannot be managed only pointing to individual responsibilities of people living with obesity. There is a missing link here, and this war cannot be won in the absence of effective primary prevention measures involving changes in food production and marketing, and decreased release of toxic chemicals into the environment.
Literatur
1.
Zurück zum Zitat Di Ciaula A, Portincasa P (2021) The role of environmental pollution in endocrine diseases. Endocrinology and systemic diseases. Springer, Cham, pp 435–65CrossRef Di Ciaula A, Portincasa P (2021) The role of environmental pollution in endocrine diseases. Endocrinology and systemic diseases. Springer, Cham, pp 435–65CrossRef
2.
Zurück zum Zitat Di Ciaula A, Portincasa P (2019) Diet and contaminants: driving the rise to obesity epidemics? Curr Med Chem 26:3471–3482CrossRefPubMed Di Ciaula A, Portincasa P (2019) Diet and contaminants: driving the rise to obesity epidemics? Curr Med Chem 26:3471–3482CrossRefPubMed
3.
Zurück zum Zitat Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL (2011) The global obesity pandemic: shaped by global drivers and local environments. Lancet 378:804–814CrossRefPubMed Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL (2011) The global obesity pandemic: shaped by global drivers and local environments. Lancet 378:804–814CrossRefPubMed
4.
Zurück zum Zitat Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR et al (2015) Genetic studies of body mass index yield new insights for obesity biology. Nature 518:197–206CrossRefPubMedPubMedCentral Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR et al (2015) Genetic studies of body mass index yield new insights for obesity biology. Nature 518:197–206CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Portincasa P, Di Ciaula A, Bonfrate L, Stella A, Garruti G, Lamont JT (2023) Metabolic dysfunction-associated gallstone disease: expecting more from critical care manifestations. Intern Emerg Med 18:1897–1918CrossRefPubMedPubMedCentral Portincasa P, Di Ciaula A, Bonfrate L, Stella A, Garruti G, Lamont JT (2023) Metabolic dysfunction-associated gallstone disease: expecting more from critical care manifestations. Intern Emerg Med 18:1897–1918CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bhaskaran K, Douglas I, Forbes H, dos Santos Silva I, Leon DA, Smeeth L (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 384:755–65CrossRefPubMedPubMedCentral Bhaskaran K, Douglas I, Forbes H, dos Santos Silva I, Leon DA, Smeeth L (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 384:755–65CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat OECD (2019) The Heavy Burden of Obesity: The Economics of Prevention OECD Health Policy Studies. OECD, ParisCrossRef OECD (2019) The Heavy Burden of Obesity: The Economics of Prevention OECD Health Policy Studies. OECD, ParisCrossRef
8.
Zurück zum Zitat Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD (1989) Treatment of obesity by very low-calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 13(Suppl 2):39–46PubMed Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD (1989) Treatment of obesity by very low-calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 13(Suppl 2):39–46PubMed
9.
Zurück zum Zitat Singh N, Stewart RAH, Benatar JR (2019) Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials. BMJ Open 9:e029966CrossRefPubMedPubMedCentral Singh N, Stewart RAH, Benatar JR (2019) Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials. BMJ Open 9:e029966CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K et al (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 24:1553–1564CrossRefPubMedPubMedCentral Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K et al (2022) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 24:1553–1564CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY et al (2024) continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 331:38–48CrossRefPubMed Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY et al (2024) continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 331:38–48CrossRefPubMed
12.
Zurück zum Zitat Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M (2023) Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330:1795–1797CrossRefPubMed Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M (2023) Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330:1795–1797CrossRefPubMed
14.
Zurück zum Zitat Nguyen T, Wong E, Cope R (2023) Evaluating the efficacy and pharmacoeconomics of semaglutide and tirzepatide in the setting of obesity. Am J Ther 30:e347–e352CrossRefPubMed Nguyen T, Wong E, Cope R (2023) Evaluating the efficacy and pharmacoeconomics of semaglutide and tirzepatide in the setting of obesity. Am J Ther 30:e347–e352CrossRefPubMed
15.
Zurück zum Zitat Lim F, Bellows BK, Tan SX, Aziz Z, Woo Baidal JA, Kelly AS, Hur C (2023) Cost-effectiveness of pharmacotherapy for the treatment of obesity in adolescents. JAMA Netw Open 6:e2329178CrossRefPubMedPubMedCentral Lim F, Bellows BK, Tan SX, Aziz Z, Woo Baidal JA, Kelly AS, Hur C (2023) Cost-effectiveness of pharmacotherapy for the treatment of obesity in adolescents. JAMA Netw Open 6:e2329178CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Swinburn BA, Kraak VI, Allender S, Atkins VJ, Baker PI, Bogard JR et al (2019) The global syndemic of obesity, undernutrition, and climate change: the lancet commission report. Lancet 393:791–846CrossRefPubMed Swinburn BA, Kraak VI, Allender S, Atkins VJ, Baker PI, Bogard JR et al (2019) The global syndemic of obesity, undernutrition, and climate change: the lancet commission report. Lancet 393:791–846CrossRefPubMed
18.
Zurück zum Zitat Alrubaian F, Mulla Z (2023) Governments policy measures to address obesity among adults: a scoping review of the global evidence. Lancet 402(Suppl 1):S20CrossRefPubMed Alrubaian F, Mulla Z (2023) Governments policy measures to address obesity among adults: a scoping review of the global evidence. Lancet 402(Suppl 1):S20CrossRefPubMed
19.
Zurück zum Zitat Harnack L, Oakes JM, Elbel B, Beatty T, Rydell S, French S (2016) Effects of subsidies and prohibitions on nutrition in a food benefit program: a randomized clinical trial. JAMA Intern Med 176:1610–1618CrossRefPubMedPubMedCentral Harnack L, Oakes JM, Elbel B, Beatty T, Rydell S, French S (2016) Effects of subsidies and prohibitions on nutrition in a food benefit program: a randomized clinical trial. JAMA Intern Med 176:1610–1618CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Heindel JJ, Alvarez JA, Atlas E, Cave MC, Chatzi VL, Collier D et al (2023) Obesogens and obesity: state-of-the-science and future directions summary from a healthy environment and endocrine disruptors strategies workshop. Am J Clin Nutr 118:329–337CrossRefPubMed Heindel JJ, Alvarez JA, Atlas E, Cave MC, Chatzi VL, Collier D et al (2023) Obesogens and obesity: state-of-the-science and future directions summary from a healthy environment and endocrine disruptors strategies workshop. Am J Clin Nutr 118:329–337CrossRefPubMed
Metadaten
Titel
Contrasting obesity: is something missing here?
verfasst von
Agostino Di Ciaula
Piero Portincasa
Publikationsdatum
27.02.2024
Verlag
Springer International Publishing
Erschienen in
Internal and Emergency Medicine / Ausgabe 2/2024
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-024-03559-x

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Schützt das tägliche Glas Milch vor Darmkrebs?

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.